A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

StatusUnknown
PhasePhase 1
SponsorHe Huang
Started

Record status This record was last updated October 16, 2023 (before its estimated October 20, 2026 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
He Huang
12 trials monitored
See all monitored trials
Multiple Myeloma
1,273 trials monitored
See 83 trials at risk
Clinical Trial for the safety and efficacy of DeepTag-GPRC5D targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
Trial Details
NCT Number NCT06084962
Lead Sponsor He Huang
Collaborators: Yake Biotechnology Ltd.
Conditions
(from sponsor)		 Relapse/Refractory Multiple Myeloma
Related terms Multiple Myeloma, Recurrence
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov